Auvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions.
Advertisement
Sanofi United States is voluntarily recalling all Auvi-Q injections used for severe allergic reactions due to potential inaccurate dosage delivery. Lantus also faces competition from a less expensive rival that could go on sale in the US late next year, after Sanofi settled a lawsuit that allows rivals Eli Lilly and Co. and German drugmaker Boehringer Ingelheim GmbH to sell their version starting December 15, 2016. None involved patient deaths, according to the company announcement.
“As this is a life-saving device, it is important that consumers understand not only to return the recalled device, but to get a replacement epinephrine auto-injector first”, said a company spokeswoman in an emailed statement.
For questions regarding this voluntary product recall, contact the Allerject Call Center at 1-855-405-4321.
The company asks Canadian customers to take Allerjects to their local pharmacy to be replaced with an alternative epinephrine auto-injector.
Auvi-Q is packaged with two active devices and one trainer device in a corrugate box.
Advertisement
Customers should immediately contact their healthcare provider for a prescription for an alternate epinephrine auto-injector. The Paris-based company said it has kept the Food and Drug Administration abreast of the recall.
